Acquisition by Shaffer Christy L of 45000 shares of Clearside Biomedical at 1.15 subject to Rule 16b-3
CLSD Stock | USD 1.05 0.02 1.87% |
About 51% of Clearside Biomedical's shareholders are presently thinking to get in. The analysis of overall sentiment of trading Clearside Biomedical stock suggests that some investors are interested at this time. The current market sentiment, together with Clearside Biomedical's historical and current headlines, can help investors time the market. In addition, many technical investors use Clearside Biomedical stock news signals to limit their universe of possible portfolio assets.
Clearside |
Filed transaction by Clearside Biomedical Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at news.google.com
Clearside Biomedical Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Clearside Biomedical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Clearside Biomedical Fundamental Analysis
We analyze Clearside Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearside Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearside Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Clearside Biomedical is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Clearside Biomedical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Clearside Biomedical stock to make a market-neutral strategy. Peer analysis of Clearside Biomedical could also be used in its relative valuation, which is a method of valuing Clearside Biomedical by comparing valuation metrics with similar companies.
Peers
Clearside Biomedical Related Equities
GLUE | Monte Rosa | 13.72 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
TNYA | Tenaya Therapeutics | 8.51 | ||||
GBIO | Generation Bio | 6.29 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
DSGN | Design Therapeutics | 0.50 | ||||
NUVB | Nuvation Bio | 0.35 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
ORIC | Oric Pharmaceuticals | 0.70 | ||||
KRON | Kronos Bio | 1.04 | ||||
EPIX | ESSA Pharma | 1.10 | ||||
OCUL | Ocular Therapeutix | 1.69 | ||||
ERAS | Erasca | 2.05 | ||||
DRTS | Alpha Tau | 2.10 | ||||
INBX | Inhibrx | 2.37 | ||||
NXTC | NextCure | 2.50 | ||||
SNSE | Sensei Biotherapeutics | 3.57 |
Complementary Tools for Clearside Stock analysis
When running Clearside Biomedical's price analysis, check to measure Clearside Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearside Biomedical is operating at the current time. Most of Clearside Biomedical's value examination focuses on studying past and present price action to predict the probability of Clearside Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearside Biomedical's price. Additionally, you may evaluate how the addition of Clearside Biomedical to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |